Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Unichain Announces Becoming the First Layer 2 to Build Blocks in a Trusted Execution Environment (TEE)

Unichain Announces Becoming the First Layer 2 to Build Blocks in a Trusted Execution Environment (TEE)

金色财经金色财经2025/05/03 01:31
Show original

May 3 news, Unichain announced that it has become the first Layer2 to build blocks in a Trusted Execution Environment (TEE), supporting MEV protection, verifiable priority ordering, and transaction rollback protection. This upgrade reduces MEV value loss through encrypted mempool and priority ordering, and supports a publicly verifiable block construction mechanism. Additionally, with rollback protection enabled, users can avoid paying gas for failed transactions in specific applications, improving price accuracy and block space utilization

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.